Fox Business - The Power to Prosper
Search Site

Kevin Sharer

Bradway's patient dealmaking brings Onyx to Amgen

Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.In doing so, he managed to avoid falling into traps that an inexperienced CEO might make with the stakes so high, while potentially quieting some criticism over the choice of a former banker to lead the world's largest biotechnology company."Because of his experience as an investment banker, he was able to avoid a lot of the mistakes that a lot of rookie CEOs make in acquisitions," said a source familiar with the sale process, who wished to remain anonymous because he is not permitted to speak to the media."He was very disciplined and was willing to wait effectively two months for the process to play out," the person added.The deal gives Amgen an immediate new revenue stream, bolsters its drug development pipeline and places Amgen much more solidly into the oncology space, which features among...

Read More

  1. Amgen 1Q Profit Eases, But Adjusted EPS Tops Views

    Despite strong demand for its osteoporosis drug and other recently introduced products, Amgen (NASDAQ:AMGN) revealed late Wednesday a slightly weaker first-quarter p...

  2. Amgen Fourth-Quarter Profit Rises 17%

    Biotechnology giant Amgen Inc. ( NASDAQ :AMGN) on Monday said its fourth-quarter earnings rose 17% despite costs connected to new health-care laws enacted in the U.S...

  3. Amgen Posts 3Q Beat, Backs 2010 View

    Amgen Inc. ( NASDAQ :AMGN) weighed in with third-quarter results that topped the Street’s expectations, and the company backed its full-year forecast.The drug-maker ...

  1. Pfizer, Novartis may join Amgen in bidding for Onyx: sources

    Onyx Pharmaceuticals Inc , whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies ...

  2. Amgen Quarterly Net Profit Rises 5%

    Biotechnology company Amgen Inc (AMGN.O) posted a better-than-expected first-quarter profit as product sales increased 8 percent, its tax rate fell and it bought bac...

  3. Amgen, AstraZeneca To Collaborate On Inflammation Drug Pipeline

    DOW JONES NEWSWIRESDrug makers Amgen Inc. (AMGN) and AstraZeneca PLC (AZN, AZN.LN) said they reached a deal to jointly develop and commercialize five inflammatory di...

  4. Amgen 4Q Beats Street on Osteoporosis Drug Demand

    Amgen (NASDAQ:AMGN) reported late Thursday a better-than-expected fourth-quarter profit on strong demand for its top osteoporosis drugs that helped offset a decline ...

  5. Amgen Chairman, CEO Kevin Sharer To Retire

    Amgen said late Thursday Chairman and Chief Executive Officer Kevin Sharer will retire as chief executive on May 23 and then relinquish his chairman title at the end...

  6. Most Overpaid CEOs

    It’s that time of year again, when proxies are released and many business publications run lists of the highest paid CEOs at America’s large public companies. The co...

  7. Amgen 2Q Profit Beats on Record Product Sales

    Amgen (NASDAQ:AMGN) revealed Friday stronger-than-expected second-quarter earnings on record product sales, though higher costs forced its profit lower. The Thousand...

Freebase CC-BY
Source: Kevin Sharer on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL